SCHEMBL13812016

SCHEMBL13812016

Cc1ccc(S(=O)(=O)NC2=NCC(O)c3cc4c(Cl)ccnc4n32)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 2/20 0.42
KMT2A Q03164 9/20 0.42
MEN1 O00255 7/20 0.42
NPC1 O15118 2/20 0.42
HSP90AA1 P07900 1/20 0.42
RAB9A P51151 1/20 0.42
ADAM17 P78536 1/20 0.42
KLF5 Q13887 1/20 0.42
ALDH1A1 P00352 6/20 0.36
HTT P42858 5/20 0.36
GAA P10253 4/20 0.36
LMNA P02545 3/20 0.36
MAPT P10636 5/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TDP1 Q9NUW8 5/20 0.36
TP53 P04637 1/20 0.36
THRB P10828 1/20 0.36
KDM4E B2RXH2 2/20 0.35
GFER P55789 1/20 0.35
ENPP3 O14638 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14269085 0.87 SLC40A1 (0.39) SLC40A1KMT2AMEN1NPC1HSP90AA1
SCHEMBL13812083 0.82 KMT2A (0.47) SLC40A1KMT2AMEN1NPC1HSP90AA1
SCHEMBL14269084 0.79 SLC40A1 (0.35) SLC40A1KMT2AMEN1NPC1HSP90AA1
SCHEMBL4031970 0.70 SLC40A1 (0.46) SLC40A1KMT2AMEN1NPC1HSP90AA1
SCHEMBL4029308 0.69 MEN1 (0.47) SLC40A1KMT2AMEN1NPC1HSP90AA1
SCHEMBL21490844 0.67 PTGDR2 (0.46) SLC40A1KMT2AMEN1NPC1HSP90AA1
SCHEMBL1749021 0.62 PTGDR2 (0.44) SLC40A1KMT2AMEN1NPC1HSP90AA1
SCHEMBL19643722 0.61 PTGDR2 (0.45) ALDH1A1HTTLMNAKDM4EL3MBTL1
SCHEMBL1749228 0.60 L3MBTL1 (0.59) ALDH1A1HTTKDM4EENPP3ENPP1
SCHEMBL29634511 0.60 L3MBTL1 (0.59) ALDH1A1HTTKDM4EENPP3ENPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1307454-B1 DERIVATIVES OF VARIOLIN B PHARMA MAR SA (ES) 2009-06-03 EP disclosed
US-7329666-B2 Derivatives of variolin B PHARMA MAR, S.A. (ES) 2008-02-12 US disclosed
US-7329666-B2 Derivatives of variolin B PHARMA MAR, S.A. (ES) 2008-02-12 US disclosed
US-20080033001-A1 Derivatives of Variolin B UNIVERSIDAD DE BARCELONA (ES) 2008-02-07 US disclosed
US-20080033001-A1 Derivatives of Variolin B UNIVERSIDAD DE BARCELONA (ES) 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033001-A1 Derivatives of Variolin B ARG2, SDHB, OAT SLC40A1 535/4885KMT2A 1287/4885MEN1 2136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.